EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Navidea Biopharmaceuticals's Enterprise Value is $-2.60 Mil.
Navidea Biopharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.91 Mil. Therefore, Navidea Biopharmaceuticals's EV-to-FCF for today is 0.26.
The historical rank and industry rank for Navidea Biopharmaceuticals's EV-to-FCF or its related term are showing as below:
NAVBQ'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.26
Current: 0.26
During the past 13 years, the highest EV-to-FCF of Navidea Biopharmaceuticals was 0.26. The lowest was 0.00. And the median was 0.00.
NAVBQ's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 14.885
vs NAVBQ: 0.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Navidea Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:
Navidea Biopharmaceuticals's share price for today is $0.0001.
Navidea Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Navidea Biopharmaceuticals EV-to-FCF Related Terms
Navidea Biopharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Navidea Biopharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navidea Biopharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Navidea Biopharmaceuticals's EV-to-FCF falls into.
Navidea Biopharmaceuticals's current Enterprise Value is $-2.60 Mil.
Navidea Biopharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals (NAVBQ) has a EV-to-FCF of 0.26 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Navidea Biopharmaceuticals and its competitors.
Is Navidea Biopharmaceuticals' EV-to-FCF too high?
Navidea Biopharmaceuticals' current EV-to-FCF is 0.26. The Biotechnology industry median EV-to-FCF is 14.89. Navidea Biopharmaceuticals' value of 0.26 is 98.3% below this industry median. Overall, Navidea Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Navidea Biopharmaceuticals' EV-to-FCF compare to PKBO and RSPI?
Navidea Biopharmaceuticals' EV-to-FCF of 0.26 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 14.89. Navidea Biopharmaceuticals' value of 0.26 is 98.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.89, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Navidea Biopharmaceuticals's current EV-to-FCF of 0.26 is 98.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Navidea Biopharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navidea Biopharmaceuticals's current EV-to-FCF is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navidea Biopharmaceuticals stock overvalued right now?
Navidea Biopharmaceuticals (NAVBQ) has a current EV-to-FCF of 0.26. The current EV-to-FCF is 0.26 and 98.3% below the Biotechnology industry median of 14.89. Navidea Biopharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Navidea Biopharmaceuticals (NAVBQ), the current EV-to-FCF is 0.26 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score
Get the complete analysis for NAVBQ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAVBQ has been successfully added to your 
